You've Done Everything Right, Yet Fertility Remains Out of Reach. Here's the Biological Reason.

MTHFR encodes an enzyme that converts folate into methylfolate, the active form your cells use to build DNA, regulate genes, and support the methylation cycle. This enzyme is working in every cell in your body, but it is absolutely critical during pregnancy because embryo development demands heavy methylation activity. Without adequate methylation, neural tube closure fails, chromosomal errors accumulate, and miscarriage risk rises.

The MTHFR C677T variant, carried by roughly 40% of people with European ancestry, reduces enzyme efficiency by 40-70%. That means even if you’re taking folic acid supplements, your cells are converting them into usable methylfolate at a fraction of the rate they should be. You can eat a perfect diet rich in folate and still be functionally depleted at the cellular level during the critical first weeks of pregnancy.

The result is that each month your eggs are developing in an environment with suboptimal methylation support. Embryos that do develop may have chromosomal instability. If pregnancy does occur, miscarriage risk is elevated, particularly in the first trimester. You may conceive but struggle to carry. Standard prenatal vitamins with folic acid do not solve this problem because your body cannot convert folic acid efficiently.

FSHR encodes the follicle-stimulating hormone receptor, the antenna on ovarian cells that listens for FSH. When FSH binds to this receptor, it tells your ovary to grow follicles and produce estrogen. If your FSHR receptor is less responsive, your ovaries simply do not hear the signal as well, even if your FSH levels are normal.

The N680S variant, common in roughly 10-15% of people, reduces the ovary’s sensitivity to FSH stimulation. Women with this variant often have poor ovarian response to fertility medications, requiring much higher doses of gonadotropins to stimulate the same number of follicles as other women. Standard fertility protocols use a one-size-fits-all approach to FSH dosing. If you have this variant, you are likely understimulated on a standard dose.

Clinically, this appears as poor ovarian reserve, low antral follicle count, or disappointing egg retrieval numbers during IVF. But your actual ovarian reserve may be fine. Your ovaries are just not responding to standard FSH doses because your receptors are less sensitive. This is profoundly relevant for IVF protocol selection.

ESR1 encodes the estrogen receptor, the protein that allows your uterine lining (endometrium) to respond to estrogen and prepare for implantation. This receptor controls endometrial receptivity, the brief window when the uterus can actually accept an embryo. If your estrogen receptor is less sensitive, your endometrium may never achieve optimal receptivity, even with rising estrogen levels.

ESR1 variants (PvuII, XbaI polymorphisms) are carried by roughly 40% of people and directly affect how sensitive your endometrial cells are to estrogen signaling. Some women with unfavorable ESR1 variants have chronically reduced endometrial receptivity, meaning their uterus is biologically less capable of accepting an embryo, regardless of how many eggs they produce. You can have perfect ovulation and perfect embryos and still not implant because your endometrium is not receptive.

This manifests as implantation failure, repeated chemical pregnancies, or a pattern of excellent egg quality and embryo development but persistent failure to achieve a clinical pregnancy. Standard fertility workups rarely test endometrial receptivity directly. You may have been told your embryos are genetically normal and your FSH is fine, yet you still do not get pregnant because your endometrium is not receptive.

CFTR encodes a chloride ion channel involved in many tissues, most famously the lungs in cystic fibrosis. But CFTR is also critical for development of the vas deferens, the tube that transports sperm from the testes. Certain CFTR variants do not cause cystic fibrosis but do disrupt vas deferens development.

CFTR carrier variants, present in roughly 1 in 25 people of European ancestry, can cause congenital bilateral absence of the vas deferens (CBAVD) in men. Men with CBAVD have normal sperm production and normal testosterone, but no anatomical route for sperm to exit the body, resulting in azoospermia (no sperm in ejaculate) with no obvious cause. This is often discovered during fertility evaluation when a man’s semen analysis shows no sperm but his hormones and testes are normal.

For years, this is labeled idiopathic infertility. Doctors may recommend testicular aspiration for IVF, without ever mentioning that a CFTR variant could be responsible. The man may also be a carrier for cystic fibrosis without realizing it, with implications for genetic counseling and reproductive risk.

DAZL (deleted in azoospermia-like) is part of the AZF (azoospermia factor) region on the Y chromosome, a region that encodes genes absolutely required for sperm cell production. The Y chromosome contains a few dozen genes, and most of them exist nowhere else in the genome. These are the genes your sperm cells need to exist.

Deletions in the AZFa, AZFb, or AZFc regions affect roughly 1 in 2,000-3,000 men with infertility and cause azoospermia or severe oligospermia (very few sperm). Men with these deletions lack the genetic material required to produce sperm in normal quantities or at all, and this cannot be fixed with medication or lifestyle changes. It is a permanent genetic loss.

When a man presents with azoospermia, urologists test for DAZL/AZF deletions because the results determine whether fertility is even possible. If the deletion is in AZFa or AZFb, even surgical sperm retrieval will likely not be successful. If it is AZFc only, sperm may be retrievable in small numbers for IVF. Without knowing the specific deletion, you cannot know your options.

The AR gene encodes the androgen receptor, the protein in your cells that allows testosterone to exert its effects. This receptor is present in testicular cells, reproductive tissue, muscle, bone, brain, and many other tissues. Testosterone does nothing unless it can bind to the androgen receptor. If your androgen receptor is less sensitive, testosterone signal is dampened.

The AR gene contains a CAG repeat, a stretch of DNA repeated a variable number of times. Longer CAG repeats reduce androgen receptor sensitivity, meaning your cells respond to testosterone less effectively, even if your testosterone level is normal or high. This is common and occurs across the population. Men with longer repeats often have lower sperm counts, reduced muscle mass despite adequate testosterone, and reduced response to testosterone replacement therapy.

For fertility, this means reduced spermatogenesis (sperm production). Your testosterone levels may look fine on bloodwork, but your testes are not responding to that testosterone signal as well as they should. Sperm production is impaired despite normal hormone levels. This is why some men with normal testosterone have oligospermia (low sperm count) with no obvious explanation.